AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
The beaten-up biopharma stock trekked higher after the development-stage company delivered a slew of pipeline updates alongside first quarter 2020 operating results. The small-cap stock has now gained 28% since the beginning of 2020, although shares of AnaptysBio have lost 73% in the last year. The development-stage company has forged collaborations with GlaxoSmithKline in cancer and Bristol-Myers Squibb in inflammatory diseases, which distributes risk and allows the business flexibility to pursue the development of wholly owned assets.
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (ANAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. The investigation concerns whether AnaptysBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / May 26, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...